跳至主要内容
临床试验/NCT02393703
NCT02393703招募中不适用

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 181 人开始时间: 2015年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
181
试验地点
1
主要终点
successful isolation of exosomes

研究概览

简要总结

The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors, without an invasive component; or other benign pancreatic disease will be eligible.
  • For third part of the study, recipient of neoadjuvant chemotherapy will be accrued to the neoadjuvant group (25 patients). Patients without neoadjuvant chemotherapy will be accrued to the non-neoadjuvant group (25 patients).

排除标准

  • The presence of metastatic disease or disease that precludes resection
  • For first and second part of the study, receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months of being enrolled in the study
  • For third part of the study, receipt of neoadjuvant radiation for the index cancer within 6 months of being enrolled in the study
  • Known clotting factor deficiency or hypercoagulable state
  • Any patient with the need or anticipated need for full anti-coagulation during hospitalization for the resection.
  • Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to resection.
  • IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion for invasive component Additionally, if at the discretion of the operating surgeon, blood collection would lead to undue morbidity, the patient will be excluded and replaced

结局指标

主要结局

successful isolation of exosomes

时间窗: 1 year

isolation of at least 100,000 microvesicles is needed for exosomes purification for down stream applications such as proteomics and RNA sequencing.

次要结局

  • evaluation of the liver microenvironment(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验